A Phase 3 interventional study of MCV4 and MPSV4 in Meningococcal Meningitis, sponsored by CanSino Biologics Inc.. Completed at 2 sites in China. Open to participants aged 7 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by CanSino Biologics Inc. · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Meningitis, Meningococcal with a site in China — 5 open to participants now, 8 under way, 5 of them phase 3. Meningitis, Meningococcal · China.
Among the 19 studies in Meningitis, Meningococcal with a site in China, this one is the 10th largest by enrollment, is one of 4 that started in 2024, is one of 10 in phase 3, and was the 14th registered.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
Browse Meningitis, Meningococcal studies →5 of the 19 studies in Meningitis, Meningococcal with a site in China are open now. Recruiting first, the newest first:
Sinovac Biotech Co., Ltd · Sites in China
Ages 3 mo–5 mo · Healthy volunteers
Sinovac Biotech Co., Ltd · Sites in China
Ages 6 mo–11 mo · Healthy volunteers
Sinovac Biotech Co., Ltd · Sites in China
Ages 12 mo–23 mo · Healthy volunteers
CanSino Biologics Inc. · Sites in China
Ages 2 mo–6 yrs · Healthy volunteers
Aimei Vacin BioPharm (Zhejiang) Co., Ltd. · Sites in China
Ages 3 mo–15 yrs · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 7 Years to 17 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3 · Phase 3 10 · Phase 4 2
First in 2015; this study’s year is marked. 4 started in 2024.
This study's enrollment of 840 is above the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Median enrollment 840 across the 19 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 19 have an industry lead sponsor. The 8 most frequent:
CanSino Biologics Inc. is the lead sponsor of 41 studies on the registry; 6 are open to participants now.
CanSino Biologics Inc. has 8 studies filed under Meningitis, Meningococcal — fewer than ten, so there is no comparison to draw.
4 of the studies in Meningitis, Meningococcal with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07505888Phase 3Sinovac Biotech Co., LtdPhase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years | 2026-11 |
| NCT07505836Phase 3Sinovac Biotech Co., LtdPhase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months | 2027-01 |
| NCT07505823Phase 3Sinovac Biotech Co., LtdPhase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 Months | 2027-04 |
| NCT07505810Phase 3Sinovac Biotech Co., LtdPhase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 Months | 2027-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 19 studies in Meningitis, Meningococcal with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, blinded, peer-controlled study. There will be 2 treatment groups, screened subjects were given study numbers in the order of enrollment and randomly assigned to the test and control groups in a 1:1 ratio. Subjects were required to complete a 1-dose immunization program with 0.5 ml of vaccine in both the test and control groups, afterwards some subjects entered the immune persistence group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: MCV4
Biological: MPSV4
1 dose of MCV4 on Day 0
1 dose of MPSV4 on Day0
Meningococcal Antibody Positive Conversion Rates and GMT for Groups A, C, Y, and W135 in All Subjects
Time frame: 30 Days After Immunization
Geometric Mean Titer (GMT) for Groups A, C, Y, and W135 in All Subjects
Time frame: 30 Days after immunization
Incidence of adverse reactions in all subjects
Time frame: Within 30 mins after immunization
Incidence of adverse reactions/events in all subjects
Time frame: Within 7 days after immunization
Incidence of adverse reactions/events in all subjects
Time frame: Within 30 days after immunization
Meningococcal antibody positivity for groups A, C, Y, and W135
Time frame: 30 days after immunization
Geometric mean multiplicity of increase (GMI) for groups A, C, Y, and W135
Time frame: 30 days after immunization
Antibody titer ≥1:128 ratio for groups A, C, Y, and W135
Time frame: 30 days after immunization
Meningococcal Antibody Positivity for Groups A, C, Y, and W135 in Selected Subjects
Time frame: 180 days after immunization
GMT for Groups A, C, Y, and W135 in Selected Subjects
Time frame: 180 days after immunization
GMI for Groups A, C, Y, and W135 in Selected Subjects
Time frame: 180 days after immunization
Antibody Titer ≥1:128 Ratio for Groups A, C, Y, and W135 in Selected Subjects
Time frame: 180 days after immunization
Incidence of Serious Adverse Events (SAEs) for all subjects
Time frame: Within 180 days after immunization
Ran from Dec 2024 to primary completion in Feb 2025, 2 months.
Of 25 phase 3 interventional studies under Meningitis, Meningococcal, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 20. This study's 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.